Abstract 2494
Background
CAR-T cells are a new cancer treatment, where T cells are taken from the patient and modified in a laboratory to target cancer cells. There have been some promising results from early clinical trials, which have led to two products being made available to patients in the NHS. Axicabtagene ciloleucel for relapsed/refractory B-cell lymphoma patients and tisagenlecleucel for relapsed/refractory B-cell lymphoma patients and relapsed/refractory B-ALL patients under the age of 25. There are multiple clinical trials in progress throughout Europe, mostly in the haematology setting, with some in oncology. There are significant toxicities to this treatment modality and this is a complex heavily pre-treated patient population. Education of the wider nursing and multi professional team is therefore crucial. A new Lecturer Practitioner role was established, to focus on CAR-T. This poster explores nurses’ learning needs associated with introducing CAR-T therapy in a specialist cancer hospital in London, UK.
Methods
Data has been collected through evaluation of previous nursing educational initiatives in CAR-T therapy, which aimed to identify further learning needs. Further data collection is in development.
Results
Although this work is on-going, initial findings indicate that nurses require more education and support particularly around managing toxicities and patient expectations. Challenges for educating nurses also include uncertainties around the long-term effects of this treatment modality.
Conclusions
CAR-T therapy is being implemented at multiple centres throughout the UK/Europe and it is evident that there are a multitude of future opportunities for career development for nurses in this area. The role of a Lecturer Practitioner in CAR-T at a specialist cancer hospital has been created to address some of the educational needs of the nursing and multi-professional team. The post holder is involved in a wide range of educational initiatives, from national bespoke study days and academic cancer care modules to ward based teaching. It is clear that there is a need for a role that combines clinical practice and academia, bridging the theory to practice gap and providing expert clinical knowledge to nurses caring for these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Ellard: Honoraria (self): MolMed; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Kite Gilead. All other authors have declared no conflicts of interest.
Resources from the same session
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract
5218 - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Presenter: Bram De Laere
Session: Poster Display session 3
Resources:
Abstract